SEARCH

SEARCH BY CITATION

References

  • 1
    Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23:164173.MEDLINE
  • 2
    Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome. Gastroenterology 2002; 122:16581676.MEDLINE
  • 3
    Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001; 34:12421251.MEDLINE
  • 4
    Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, Navasa M, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229236.MEDLINE
  • 5
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:11511157.MEDLINE
  • 6
    Guevara M, Ginès P, Fernandez-Esparrach G, Sort P, Salmerón JM, Jiménez W, Arroyo V, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 1:3541.
  • 7
    Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine. Hepatology 1999; 30:870875.MEDLINE
  • 8
    Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29:565570.MEDLINE
  • 9
    Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33:4348.MEDLINE
  • 10
    Mulkay JP, Louis H, Donckier V, Bouorgeois N, Adler M, Devière J, Le Moine O. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64:1519.MEDLINE
  • 11
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122:923930.MEDLINE
  • 12
    Titó Ll, Ginès P, Arroyo V, Planas R, Panés J, Rimola A, Llach J, et al. Total paracentesis associated with intravenous albumin in the management of patients with cirrhosis and ascites. Gastroenterology 1990; 98:146151.MEDLINE
  • 13
    Papper S. Hepatorenal syndrome. In: EpsteinM, ed. The Kidney in Liver Disease. 2nd ed. New York: Elsevier Biomedical, 1983; 87104.
  • 14
    Linas SL, Schaefer JW, Moore EE, Good JT Jr, Giansiracusa R. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 1986; 30:736740.MEDLINE
  • 15
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29:16901697.MEDLINE
  • 16
    Arroyo V, Bataller R, Guevara M. Treatment of hepatorenal syndrome in cirrhosis. In: ArroyoV, Rodés J, Ginès P, SchrierRW, eds. Ascites and Renal Dysfunction in Liver Disease. Malden, MA: Blackwell Science, Inc., 1999; 492510.
  • 17
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28:416422.MEDLINE
  • 18
    Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47:288295.MEDLINE
  • 19
    Gonwa T, Morris C, Goldstein R, Husberg B, Klintmalm G. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome—experience in 300 patients. Transplantation 1991; 51:428430.MEDLINE
  • 20
    Fachinformation: Glycylpressin R, terlipressin acetate. Kiel: Ferring Arzneimittel GmbH, 1996.
  • 21
    Escorsell A, Ruiz del Arbol L, Planas R, Albillos A, Bañares R, Cales P, Pateron O, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 2000; 32:471476.MEDLINE
  • 22
    Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage: a systematic review and meta-analysis. Medline Embase, Cochrane Controlled Trials Register, Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Library. www.cochrane.org.
  • 23
    Pomfret EA, Pomposelli JJ, Jenkins RL. Live donor liver transplantation. J Hepatol 2001; 34:613624.MEDLINE
  • 24
    Rimola A, Gavaler JS, Schade RR, El-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93:148156.MEDLINE
  • 25
    Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59:361365.MEDLINE
  • 26
    Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35:11791185.MEDLINE